{"id":5289,"date":"2025-03-31T12:41:27","date_gmt":"2025-03-31T12:41:27","guid":{"rendered":"https:\/\/www.nordicbioscience.com\/?post_type=biomarker-solution&p=5289"},"modified":"2025-06-03T07:55:48","modified_gmt":"2025-06-03T07:55:48","slug":"intestinal-fibrosis","status":"publish","type":"biomarker-solution","link":"https:\/\/www.nordicbioscience.com\/biomarker-solution\/gastrointestinal-diseases\/intestinal-fibrosis\/","title":{"rendered":"Intestinal Fibrosis"},"content":{"rendered":"
\n \n
\n
\n
\n
\n

NordicIBDTrace\u2122<\/h2>\n \n\n <\/div>\n
\n

During chronic inflammation, immune cells secrete pro-inflammatory cytokines that activate tissue-resident fibroblasts, the primary producers of ECM proteins such as collagen. This fibro-inflammatory process leads to progressive tissue stiffening and, ultimately, stricture formation.<\/p>\n

Fibrostenotic Crohn\u2019s disease<\/a> has been associated with non-response to therapeutics, with approximately 50% of patients developing fibrotic complications during their disease course.<\/p>\n

In ulcerative colitis, fibrosis is increasingly being recognized as a clinically relevant complication that impacts long-term disease management.<\/p>\n

The Nordic<\/b>IBDTrace<\/b>\u2122 <\/b>biomarker panel offers a means to quantify intestinal fibro-inflammation<\/b>, providing valuable insights that can support the development of antifibrotic therapies aimed at preventing or treating fibrostenotic complications.<\/p>\n <\/div>\n <\/div>\n

\n \n Browse NordicIBDTrace\u2122 \n \n <\/svg>\n \n <\/a>\n <\/div>\n <\/article>\n
\n
\"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n
\n\n
\n

NordicPRO-C6\u2122: A marker of intestinal fibrosis<\/h2>\n

The nordicPRO-C6\u2122<\/a> biomarker measures endotrophin, a bioactive fragment with both inflammatory and fibrotic properties. Elevated nordicPRO-C6\u2122 levels have been observed in patients with stricturing Crohn\u2019s disease (B2, Montreal classification) and those with MRE-confirmed strictures. Furthermore, patients who experience stenotic disease progression exhibit higher levels of nordicPRO-C6\u2122 than those who do not progress, highlighting its potential as a biomarker for identifying high-risk patients, monitoring fibrosis progression, and assessing the impact of anti-fibrotic therapies in clinical trials.<\/p>\n

<\/p>\n

\"\"
NordicPRO-C6\u2122 levels are elevated in patients with stenosis, as well as those who experience stenotic disease progression compared to those who do not progress<\/em><\/figcaption><\/figure>\n

<\/p>\n <\/div>\n <\/div>\n<\/section>\n\n\n\n\n

\n \n
\n
\n
\n
\n

Collagen formation biomarkers for tissue fibrosis<\/h2>\n \n\n <\/div>\n
\n

Biomarkers of collagen formation, including type III (nordicPRO-C3\u2122)<\/a>, V (PRO-C5<\/a>) VI (nordicPRO-C6\u2122<\/a>) , XI (PRO-C11<\/a>), and XVI (PRO-C16<\/a>), have been associated with stenotic Crohn\u2019s disease and can be used to differentiate patients with fibrosis from those without.<\/p>\n

Additionally, these biomarkers can aid in assessing changes in fibrosis in response to anti-fibrotic treatment, supporting therapeutic evaluation and internal decision making in clinical trials.<\/p>\n <\/div>\n

\n

Publications<\/h3>\n